Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors.

Clicks: 340
ID: 99249
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #578 of 2,056 articles by views in PloS one

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 2,056 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Here we describe an industry-wide collaboration aimed at assessing the binding properties of a comprehensive panel of monoclonal antibodies (mAbs) against programmed cell death protein 1 (PD-1), an important checkpoint protein in cancer immunotherapy and validated therapeutic target, with well over thirty unique mAbs either in clinical development or market-approved in the United States, the European Union or China. The binding kinetics of the PD-1/mAb interactions were measured by surface plasmon resonance (SPR) using a Carterra LSA instrument and the results were compared to data collected on a Biacore 8K. The effect of chip type on the SPR-derived binding rate constants and affinities were explored and the results compared with solution affinities from Meso Scale Discovery (MSD) and Kinetic Exclusion Assay (KinExA) experiments. When using flat chip types, the LSA and 8K platforms yielded near-identical kinetic rate and affinity constants that matched solution phase values more closely than those produced on 3D-hydrogels. Of the anti-PD-1 mAbs tested, which included a portion of those known to be in clinical development or approved, the affinities spanned from single digit picomolar to nearly 425 nM, challenging the dynamic range of our methods. The LSA instrument was also used to perform epitope binning and ligand competition studies which revealed over ten unique competitive binding profiles within this group of mAbs.
Reference Key
brown2020assessingplos Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Brown, Michael E;Bedinger, Daniel;Lilov, Asparouh;Rathanaswami, Palaniswami;Vásquez, Maximiliano;Durand, Stéphanie;Wallace-Moyer, Ian;Zhong, Lihui;Nett, Juergen H;Burnina, Irina;Caffry, Isabelle;Lynaugh, Heather;Sinclair, Melanie;Sun, Tingwan;Bukowski, John;Xu, Yingda;Abdiche, Yasmina Noubia;
Journal PloS one
Year 2020
DOI
10.1371/journal.pone.0229206
URL
Keywords
prescription expenditure lipid-lowering drugs restrictive reimbursement

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.